[Atrial fibrillation. PALLAS study: when dronedarone becomes a risk].
Peter
P
Overbeck
D000638:Amiodarone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D002423:Cause of Death; D000075202:Contraindications; D000077764:Dronedarone; D057239:Early Termination of Clinical Trials; D023381:Endpoint Determination; D006801:Humans; D010343:Patient Admission / Q000706:statistics & numerical data; D012307:Risk Factors; D015996:Survival Rate
D000889:Anti-Arrhythmia Agents; D000077764:Dronedarone; D000638:Amiodarone